This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jeffrey A. Perlman, MD, MSc; Karen Johnson, PhD, MD; Susan Nayfield, MD, MSc; Leslie G. Ford, MD
National Cancer Institute Bethesda, Md

JAMA. 1995;273(8):619-620.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The Special Communication on ERT in breast cancer survivors¹ noted potential National Cancer Institute support of new clinical investigations. A National Cancer Institute Working Group considered certain hormone combinations for short-term menopausal symptom relief studies but did not support the contention by Cobleigh et al that ERT or ERT with tamoxifen can yet be safely tested in large phase III trials.²

The article provided limited evidence on ERT safety for breast cancer survivors. First, data on recurrence and survival effects were presented but were limited to studies of "past" or "ever recorded" ERT use. These studies were confounded by the reversible nature of hormonal promotion; meaningful contingencies of current or long-term use were not presented.² The recurrence/survival studies were also too small to address the central question of the relative risk (RR) of tumor reactivation or second primary tumor. Survival studies may also have . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?